trazimera 440 mg pulver für ein konzentrat zur herstellung einer infusionslösung
pfizer ag - trastuzumabum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: trastuzumabum 440 mg, histidinum, histidini hydrochloridum monohydricum, polysorbatum 20, saccharum, pro vitro. solvens: alcohol benzylicus 220 mg, aqua ad iniectabile, pro vitro. - metastasiertes mammakarzinom, mammakarzinom im frühstadium, magenkarzinom und karzinom des gastroösophagealen Übergangs - biotechnologika
kanjinti 150 mg pulver für ein konzentrat zur herstellung einer infusionslösung
amgen switzerland ag - trastuzumabum - pulver für ein konzentrat zur herstellung einer infusionslösung - vorbereitung cryodesiccata: trastuzumabum 150 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, für glas. - onkologikum - biotechnologika
kanjinti 440 mg pulver für ein konzentrat zur herstellung einer infusionslösung
amgen switzerland ag - trastuzumabum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: trastuzumabum 440 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. solvens: alcohol benzylicus 220 mg, aqua ad iniectabile, solutio reconstituta corresp. trastuzumabum 21 mg/ml. - onkologikum - biotechnologika
imatinib koanaa
koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastische mittel - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienten, die einen niedrigen oder sehr niedrigen rückfallrisiko sollten nicht erhalten eine adjuvante behandlung. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. außer bei patienten mit neu diagnostiziertem chronischen phase der cml gibt es keine kontrollierten studien zeigen einen klinischen nutzen oder erhöhte überlebenschancen für diese krankheiten.
roundup®powerflex
bayer ag - wasserlösliches konzentrat - 480 g/l glyphosat ((als kalium-salz 588 g/l)) - top
teriflunomid stada 14 mg filmtabletten
stadapharm gmbh (3364435) - filmtablette - 14 mg
teriflunomid - 1 a pharma 14 mg filmtabletten
1 a pharma gmbh (8013083) - filmtablette - 14 mg
teriflunomid hexal 14 mg filmtabletten
h e x a l aktiengesellschaft (3079284) - filmtablette - 14 mg
teriflunomid al 14 mg filmtabletten
aliud pharma gmbh (3270510) - filmtablette - 14 mg
teriflunomid-ratiopharm 14 mg filmtabletten
ratiopharm gmbh (3087881) - filmtablette - 14 mg